Tauklarify tau PET adds a tau tangles picture that complements amyloid PET, it does not replace it. Younger-onset families avoid overreading the headline by treating either scan as one piece alongside clinical and cognitive evidence plus follow-up.
Tauklarify (florquinitau F 18 injection, formerly MK-6240) is an F18-labeled tracer for PET brain imaging. The FDA approved it on August 13, 2026 for adults with cognitive impairment evaluated for Alzheimer's to identify tau neurofibrillary tangle pathology, according to the FDA approval notice. Lantheus says tau imaging provides information complementing amyloid PET and other tools rather than replacing them, according to the Lantheus approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official notice from Lantheus — Use this primary source to verify the official announcement.
Table of Contents
- What does each PET scan show?
- Why does tau get attention in younger-onset families?
- What can a Tauklarify result not decide alone?
- How should families handle the headline result?
What does each PET scan show?
Amyloid PET shows amyloid-beta plaques, one Alzheimer-related protein buildup. Tau PET shows tau neurofibrillary tangles, a different protein buildup tied more closely to nerve-cell injury. That difference matters for timing.
Amyloid can appear years before strong symptoms. Tau tends to track closer to where damage and decline are happening. So doctors use the scans together. One flags Alzheimer-related amyloid presence, the other helps map tau pathology in the workup.
Why does tau get attention in younger-onset families?
Tau PET explained about 40% of variation in future brain degeneration versus about 3% for amyloid PET in NIH-summarized UCSF research. Participants under 65 carried higher tau and faster tissue loss in that research. That link can make a tau headline feel like a forecast.
Families facing onset before 65 often want a clear timeline for work, childcare, and care plans. Appropriate-use criteria rate amyloid and tau PET as appropriate when suspected Alzheimer's causes mild cognitive impairment or dementia with onset before 65. The rating supports careful testing in this group, not home interpretation of one image.
What can a Tauklarify result not decide alone?
Approval rested on two studies with five blinded readers per study classifying scans from more than 500 participants against cognitive status plus amyloid-beta PET. That design supports use in an Alzheimer evaluation, not as a standalone disease label. The approved label states safety and effectiveness are not established for non-Alzheimer's tauopathies.
A tau-positive scan does not by itself identify which tau disease is present. Prescribing information also warns performance may be lower at earlier pathologic stages, a negative scan does not necessarily exclude tau pathology, and a positive scan does not necessarily confirm it, according to the Practical Neurology report. Uncertain cases need additional evaluation.
How should families handle the headline result?
Ask what question each test answered. Keep amyloid, tau, exam findings, history, labs, and cognitive testing on the same page.
Bring this short checklist to follow-up: Write down exact words from the report before calling relatives. Ask the clinician to explain whether the tau result changed the diagnosis, the confidence level, or only the next test.
- Which scan was positive, negative, or uncertain, and in which brain regions
- What diagnosis is still being considered or ruled out
- What other causes of thinking changes were checked
- What repeat testing, referral, trial screening, or care step comes next
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: How Younger-Onset Alzheimer’s Families Can Avoid Overreading the Headline
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Younger-Onset Alzheimer’s Families Can Avoid Overreading the Headline
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Younger-Onset Alzheimer’s Families Can Avoid Overreading the Headline
